CASP3 and plasma cell myeloma: Furthermore, the combination of bortezomib and HDS also demonstrated synergistic anti-myeloma activity, including inducing apoptosis by upregulating cleavage of caspase-3, -8, and -9 (Fig. 5E, F; Additional file 1: Fig. S5).